Effectiveness of interactive dashboards to optimise prescribing in general practice: A systematic review

Caroline McCarthy* (0000-0002-2986-5994)[1], Patrick Moynagh (0009-0004-1233-3176)[1], Áine Mannion[1], Ashely Wei[1], Barbara Clyne (0000-0002-1186-9495)[2], Frank Moriarty (0000-0001-9838-3625)[3]

[1]Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland
[2] Department of Public Health & Epidemiology, School of Population Health, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland
[3] School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin 2, Ireland

*Corresponding author: carolinemccarthy@rcsi.com

Author roles:

Caroline McCarthy: Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Patrick Moynagh: Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing

Aine Mannion: Investigation, Writing – Review & Editing

Ashley Wei: Investigation, Writing – Review & Editing

Barbara Clyne: Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing

Frank Moriarty: Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing

Data Availability:

No new primary data were collected for this study, as the review synthesises publicly available data from published studies. All data generated or analysed during this study are included in this published

28   article and its supplementary information files. This includes the search strategies used for each

29   database, details of the included studies, and any additional data extracted during the review process.

30   The study protocol is available as an open-access publication and can be accessed directly at

31   https://hrbopenresearch.org/articles/7-44.

Competing interests:

33   The authors have declared that no competing interests exist.

Funding:

35   CMC is funded by a HRB post-doctoral Clinician Scientist Fellowship award (CSF- 2023-012)

36   https://www.hrb.ie/funding/. PM is funded by an ICGP Post CSCST Fellowship award. The funders had

37   no role in study design, data collection and analysis, decision to publish, or preparation of the

38   manuscript.

Abbreviations:

PIP, potentially inappropriate prescribing; EHR, electronic healthcare records; RCT, randomised
controlled trial; ITS, interrupted time series; CBA, controlled before and after study; EPOC, Effective
Practice and Organisation of Care; TIDieR, Template for Intervention Description and Replication; Abx,
antibiotic; SABA, short acting beta agonist inhaler; LABA, long acting beta agonist inhaler; NSAID, non-
steroidal anti-inflammatory drug; eGFR, estimated glomerular filtration rate; CKD, chronic kidney
disease; CVD, cardiovascular disease; CCG, clinical commissioning group; NICE, National Institute for
Clinical Excellence; RTI, respiratory tract infection; CDSS, clinical decision support-system; ARR,
absolute risk reduction; OR, odds ratio; DDD, defined daily dosage; CI, confidence interval; RP, risky
prescribing; AF, atrial fibrillation

Word Count (excluding abstract/tables/references): 3899

Abstract	247
Introduction	493
Methods	654
Results	1595
Discussion	1157
	3899

51   Tables: 2, Figures: 3

52   References: 40

Abstract

Background

The World Health Organisation's Medication Without Harm campaign aims to reduce severe avoidable medication related harm by 50%. This systematic review explored the characteristics of interventions that provide visual and longitudinal feedback on prescribing, or interactive dashboards, in general practice and the effect of these interventions on prescribing-related outcome measures.

Methods

This systematic review was registered prospectively and reported in line with PRISMA guidelines. Multiple databases and grey literature were searched in November 2023 to identify interventional studies that explored the effect of interactive dashboards on prescribing-related outcomes in general practice. Two independent researchers conducted screening, data extraction, and risk of bias assessment. Interventions were described narratively, and a random-effects meta-analysis was performed for comparable studies.

Results

Eight randomised controlled trials, one controlled before-and-after study and three interrupted time series were included. Six studies reported a significant positive effect on prescribing-related outcomes, with an effect seen more often for studies focusing on potentially inappropriate prescribing (PIP) (four out of six). Two of the six studies that focused on antibiotic prescribing demonstrated a significant effect. A meta-analysis of three RCTs involving 160 general practices and 198,135 patients demonstrated the overall odds of PIP was 0.91 (95%CI: 0.77-1.06 I^2=71.8%) in the intervention compared to control group.

Conclusion

Interactive dashboards show promise for supporting safe and effective prescribing in general practice. Future research should focus on developing core outcome sets to facilitate future meta-analyses of

effectiveness as well as optimising their implementation and understanding how to sustain user

engagement.

Lay summary

The World Health Organization's "Medication Without Harm" campaign aims to reduce preventable

medication-related harm by 50%. One way to support safe prescribing is by giving prescribers ongoing

feedback on their prescribing habits using interactive dashboards. These dashboards provide visual

and long-term data to help guide safer and more effective prescribing. This research looked at how

interactive dashboards have been used in general practice and whether their use improves

prescribing. Researchers systematically searched the published literature and identified 12 relevant

studies. Some studies involved randomly assigning doctors or practices to either use the dashboards

or continue usual care. Others compared prescribing practices before and after introducing

dashboards or looked at practices that used dashboards compared to those that did not. Six of the

studies showed improvements in prescribing, especially when focused on reducing high-risk

prescriptions. The data for three studies that looked at high-risk prescribing involving 160 general

practices and 198,135 patients showed that interactive dashboards may reduce the chance of unsafe

prescribing by 8.8%. However, this result was not statistically significant, and the difference in results

between studies means the true effect remains uncertain. The findings highlight the potential of

interactive dashboards to support safer prescribing in general practice, though further research is

needed.

Key Words: Interactive dashboards, potentially inappropriate prescribing, audit and feedback,

preventable drug related morbidity, polypharmacy, comparative benchmarking, electronic health

records, routine prescription data.

Introduction

Prescribing is the most common healthcare intervention and advances in therapeutics have improved the lives and life expectancy of many people living with chronic illness.[1] However, alongside these improvements there has been an increase in potentially inappropriate prescribing (PIP) which has potential negative consequences for individuals, society and healthcare systems.[2] Prescribing for older patients with multiple chronic illnesses is particularly challenging as prescribers must contend with both potential drug-drug and drug-disease interactions.[3] The reasons for PIP are complex and multifaceted and include systems failures, particularly at the interface between primary and secondary care, individual patient factors such as increasing age and multimorbidity, clinician factors such as knowledge and attitudes and broader societal attitudes about the roles and benefits of medicines.[4] To both measure and address this, a variety of explicit criteria have been developed for use in both research and clinical practice.[5] These measures tend to focus on highly prevalent PIP or those with the potential for significant harm. More recently there has been a shift towards identifying and addressing low-value prescribing, which on a population level can result in harm both directly (e.g. experiencing adverse effects from medicines that are not providing benefit) and indirectly (e.g. contributing to non-adherence and through the opportunity cost of other cost-effective interventions not resourced due to spending on low-value medicines).[6] The application of explicit measures of medication appropriateness have been demonstrated to be effective at improving prescribing and have the advantage of being relatively reproducible, reliable and easy to apply to large numbers of people.[7]

With recent advancements in electronic healthcare records (EHR) and prescribing, it is now possible to apply explicit criteria to routine prescribing or dispensing datasets. OpenPrescribing.net is a prominent example, where the vast amount of anonymous prescription data published by NHS England each month is analysed and presented on a web platform to allow for comparative benchmarking between practices.[8] However, when using publicly available anonymous data, only a

subset of explicit criteria can be applied as patient-level data such as age and co-morbidities are not

included. In addition, it is challenging for clinicians to identify and act on individual instances of sub-

optimal prescribing. One approach to combine both audit and feedback and clinical decision support

(both of which have been identified as effective methods to improve prescribing[9,10]), while

maintaining anonymity, has been to embed code within practice systems and export aggregate-level

data.[11] This aggregated data can then be fed back to individual practices in the form of interactive

dashboards and allow for comparative benchmarking. This approach ensures that individual patient

identities are protected while allowing practices to compare their performance, identify areas for

improvement and act on individual instances of high-risk prescribing.

Given advancements in data infrastructure in general practice and the need to address both high-risk

and low value prescribing, this systematic review aimed to explore characteristics and effectiveness

of interactive dashboard interventions on prescribing outcomes in general practice with the additional

goal of informing future intervention development and e-prescribing infrastructure.

Methods

The methods have been described previously in our published protocol.[12] This systematic review was

prospectively registered on PROSPERO (CRD42023481475), conducted in line with guidance set out in

the Cochrane Handbook for Systematic Reviews of Interventions,[13] and reported in adherence to

PRISMA statement, S1 Appendix.[14]

Data sources and search strategy

A systematic literature search was conducted 22nd November 2023 in the following databases;

PubMed, EMBASE, MEDLINE (OVID), PsycINFO (EBSCOhost), CINAHL (EBSCOhost), Scopus and the

Cochrane Library (OVID). This was supplemented by grey literature searches in OpenGrey, CADTH Grey

Matters and the International Clinical Trials Registry Platform (ICTRP) as well as backward and forward

citation chasing using an automated citation chaser.[15] There were no restrictions placed on language

or year of publication. Search terms included keywords to capture the intervention (e.g. "interactive

dashboard", "clinical audit", "medical audit", "benchmarking", "data visualisation") the population

(e.g. "general practitioner", "primary care*") and the outcomes (e.g. "PIP", "prescribing"). See S2

Appendix for electronic search reports.

Eligibility criteria

All interventional designs were eligible for inclusion including randomised controlled trials (RCTs) (e.g.

cluster RCTs, step wedged RCTs and individually randomised RCTs) and non-randomised interventional

studies for example interrupted time series (ITS) design and controlled before and after studies as

recommended by the Cochrane Effective Practice and Organisation of Care (EPOC) group, see S3

Appendix for a summary of inclusion and exclusion criteria. The population of interest was primary

care prescribers including non-medical prescribers working in primary care (e.g. pharmacists). An

interactive dashboard was defined as a platform designed to provide ongoing feedback of real-time

(defined as no older than one year) prescribing data in a visual format and that allowed for

comparative benchmarking against peers or a set standard. A true interactive dashboard allows direct

manipulation of data with visual analytic tools, however studies that did not have an interactive

element but provided feedback of multiple parameters and/or configurations from the dataset were

also included. Simple clinical decision support interventions or audit and feedback interventions that

did not give longitudinal and ongoing feedback of real-time data were both excluded. Multi-faceted

interventions that included interactive dashboards alongside other components such as education,

clinical decision support or targeted behavioural change strategies were included. The outcome of

interest was any prescribing related outcome measure such as explicit prescribing criteria or

prescribing rates where a higher rate is described as reflecting lower quality (e.g. antibiotic,

benzodiazepine or opioid use).

Study selection and data extraction

Identified records were uploaded to Covidence and independently assessed for inclusion based on

title and abstract and then full text papers by two researchers (CMC, PM, AM, AW, FM), blinded to

each other's decisions, with disagreement resolved by consensus. Data was extracted independently

by two researchers using a purposely developed data extraction tool in Covidence (CMC, PM), see S3

Appendix for a list of all data points extracted. Methodological quality assessment was assessed

independently by two reviewers using the Cochrane EPOC risk of bias tool (CMC, PM).[16]

Analysis

The Template for Intervention Description and Replication (TIDieR) checklist[17] was used as a

framework to narratively summarise interventions. For multi-faceted interventions this framework

was utilised to describe the interactive dashboard component alone. We categorised effectiveness

based on intervention type (for example if there was a truly interactive component to the dashboard

or whether the dashboard was part of a multi-faceted intervention), outcome of interest (e.g. high-

risk prescribing or antibiotic prescribing rates) and study design. A meta-analysis using a random-

effects model was performed where at least two studies were comparable in terms of participants,

study design and outcomes. If the desired direction of effect differed across outcomes, the measure

of association (e.g., odds ratio) was inverted to ensure comparability. Heterogeneity across studies

was assessed using the I^2 statistic, with an I^2 value greater than 50% considered indicative of

substantial heterogeneity. Although 12 studies were identified, a funnel plot was not performed due

to the heterogeneity in study design and outcomes. Instead, a narrative assessment was conducted,

acknowledging the potential limitations in detecting publication bias.

Results

Search Results

A total of 12,918 records were identified from database searching and a further 197 from other

sources. Following deduplication, 10,735 records were screened, with 121 full texts assessed for

eligibility, and 12 studies, reported in 11 different papers, were included in the review, Figure 1. See

S4 Appendix for a table of the excluded studies from full text review and their reason for exclusion.

Figure 1 Study flow diagram

Characteristics of included studies

Of the 12 included studies, three were ITSs,[18-20] one was a controlled before and after study[21] and

eight were RCTs,[22-28] S6 Appendix Characteristics of Included Studies. Four of the RCTs were a cluster

design.[23,25,27,28] Two RCTs that targeted individual physician antibiotic prescribing were individually

randomised at the physician level[22,26] and the final RCT was a stepped wedge design where six clusters

were sequentially allocated to the intervention every month.[24] One paper described randomly

assigning practices to one of two parallel cRCTs.[28] In each cRCT, the control group in one trial served

as the intervention group in the other, leading to a total of four distinct studies reported in the same

paper. These studies were conducted simultaneously with the same intervention but focused on

different outcomes. However, only two of these four studies were considered relevant for this

systematic review, as the outcomes of the other two were not relevant. Therefore, both of the

relevant studies from this paper were included in this review.[28] In seven of the included studies, one

ITS and six RCTs, participants (either individual prescribers or practices) were not aware of their

participation in the study, as the interventions were implemented at a system level or as part of

routine policy changes.[19,22,23,25-28] In two additional studies it is unclear whether practices/physicians

were recruited and consented[18,24] and in the final two studies practices from a defined region were

invited to participate.[20,21] The number of participants included in the individual studies ranged from

12 to 1,401 practices and 43 to 3,426 physicians. None of the included studies recruited individual

patients.

Six studies focused on antibiotic prescribing and used aggregated data, for example the rate of

antibiotic prescriptions per 100 consultations or the proportion of all antibiotics that were broad-

spectrum.[18,20,22-24,26] The remaining six studies focused on PIP.[19,21,25,27,28] Five of these reported the

number of patients potentially at risk and affected. The remaining study reported the mean number

of patients per practice with an inappropriate bronchodilator prescription, but did not provide the

numerator and denominator.[27]

Characteristics of interventions

The characteristics of the interactive dashboards of the included studies are described based on the

TIDieR checklist in Table 1.[17] The tailoring and modifications components of this framework were

generally not applicable as these are often more relevant to implementation programmes, where

interventions may need to be adapted to fit specific contexts or populations.[17] The interventions

identified in this systematic review were all designed for use within the context in which they were

implemented. Only one study reported a modification where antibiotic prescribing feedback was

initially based on the dispensing claim's date, but in the second year of the study this was modified to

reflect the actual prescription date.[26] Four of the 11 interventions included had a true interactive

component where the user could directly manipulate their data and had unlimited access to the

dashboard within a defined period of time.[18,19,21,23] The remaining seven interventions all provided

prescribers with longitudinal access to relatively real-time data. Six of the eleven studies included

multi-faceted interventions, where the interactive dashboard was part of a broader programme.[18,19,23-

25,28] Two of these were three arm cRCTs where one of the arms received an additional behavioural

change component.[23,25] Two dashboards also alerted prescribers to individual patients with high-risk

prescribing/ inadequate blood-test monitoring[19] or inappropriate bronchodilator prescriptions.[27]

Table 1 Characteristics of interventions

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
Interventions with a true interactive component							
Curtis 2021 [23]	Yes, arm 3 feedback included one page theory informed behavioural change component.	To increase engagement with prescribing data and change prescribing.	Link to specific metrics on publicly available prescribing dashboard with either plain or specific feedback.	Dashboard publicly available at openprescribing.net. Link and feedback provided by research team.	Link and feedback sent by post, email and fax.	May - July 2018, monthly for 3 months	Dashboard engagement measured using Google analytics.
Davidson 2023, CHOSEN [18]	Yes, web platform which included webinars on antimicrobial stewardship, how to use the dashboard and resources for patients.	To reduce inappropriate antibiotic prescribing	Web-based platform that provided interactive visualisations of abx prescribing rate that was updated on a monthly basis. Data could be explored by visit type, primary location and provider. Monthly and yearly trends were displayed with an overall rate and a target rate.	Research team	Web-based dashboard which could be accessed during study period.	Accessible at any time from February 2018	No mention of usage analytics
deLusignan 2021 [21]	No	To reduce inappropriate metformin and aspirin prescribing	Dashboard to allow GPs monitor their prescribing of metformin for patients with eGFr < 30 and >30>40 and aspirin for	Research team	Dashboard built directly into EHR	Metformin dashboard available from April-July2019. Aspirin	Not measured

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
			patients with T2DM who do not have CKD/CVD			dashboard available from July -Oct 2019	
Peek 2020, SMASH [19]	Yes, clinical pharmacists trained to deliver the intervention in partnership with general practice staff. Feedback included educational material about each of the included indicators.	To reduce hazardous prescribing and inadequate blood-test monitoring	Interactive dashboard that provided feedback on prevalence of each hazardous prescribing and inadequate blood-test monitoring indicator with comparisons to the CCG average. Data was displayed in both tabular and graph format. Individual patients at risk were also listed by NHS number.	NHS- phased roll out based on NICE guidance	Web-based interactive dashboard	Data updated on a daily basis and available to practices from April 2016.	Not measured
Interventions without a true interactive component							
Aghlmandi 2023 [22]	No	To improve abx prescribing rates amongst higher rate prescribers.	Graphic abx prescribing report comparing prescribing rates to the previous 3 months and to peers.	Research team using insurance claims data	Email to the physician	Quarterly email from December 2017- September 2019	Not measured
Dutcher 2021 [24]	Yes, once-off educational session on appropriate prescribing for RTIs	To reduce antibiotic prescribing for RTIs	Graphic report displaying overall antibiotic prescribing rate and inappropriate RTI abx prescribing rates with	Research team	Automatically generated reports with data extracted from EHR -	Monthly feedback from October 2017 - October 2018	Not measured

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
			comparisons to the average and best performing practices.		emailed to practice		
Guthrie 2016, EFFIPPS [25]	Yes, all three arms were emailed educational material. Arm 3 feedback included a 1-page theory informed behavioural change component.	To improve the safety of primary care prescribing	Graphic report comparing the practice's high risk prescribing against the rate achieved by the 25th percentile of Scottish practices with the most optimal rates in the year before feedback started.	NHS Scotland Information Services Division	Email to practice	Five emails sent quarterly from June 2012 - June 2013	Not measured
Hemkens 2017 [26]	No	To reduce antibiotic prescribing	Graphs showing monthly trend in the physician's abx prescribing rate per 100 consultations and compared to the adjusted peer average.	Research team	Posted report with access code to the study website for more detailed feedback	8 postal feedbacks between October 2013 and July 2015	Not measured
MacBride-Stewart 2022 [27]	No	To reduce inappropriate prescriptions of bronchodilator inhalers.	Tables comparing inappropriate SABA or LABA prescriptions with the rest of the health board. List of individual patients identified as receiving inappropriate prescriptions.	Report developed by research team but also had signatures from three key lead clinicians in the health board.	Emailed to secure practice address and copied to the practice's prescribing support team pharmacist.	Three times: July 2015, February 2016 and August 2016.	69.2% practices discussed feedback with team. 80.4% reviewed ≥1 patient record. 77.6% flagged ≥1. patient record.

Study ID Intervention name	Multi-faceted?	Why?	What?	Who provided it?	How and where?	When and how much?	How well?
							62.6% consulted with ≥1 patient.
Soucy 2024, OPEN Stewardship [20]	No	To reduce antibiotic prescribing rate	Personalised prescribing reports displaying overall abx prescribing rate, rates for specific conditions and comparisons against the average and 25th percentile for other intervention participants	Research team	Report emailed directed to physicians	Quarterly for 9 months	Not measured
Willis 2020, ASPIRE [28]	Yes, practices were offered two training sessions by pharmacist, CDSS prompts for risky prescribing and tools to search for high-risk patients	To target barriers to change prescribing for four quality indicators.	Practice specific report displaying temporal trends for each of the trial indicators in number and graph form. Practices were also ranked and compared to others in the CCG.	Research team	Reports sent by post and email to the practice	Quarterly from May 2015-March 2016	Implementation will be assessed via process evaluation

Although 12 studies are included in this review, two studies were reported in the same paper and used the same study processes and intervention type but focused on different outcomes. For the purpose of describing the intervention, these two studies are considered as one.

Abbreviations: Abx; antibiotic, EHR; electronic health record, eGFR; estimated glomerular filtration rate, CKD; chronic kidney disease, CVD; cardiovascular disease, CCG; clinical commissioning group, NHS; National Health Service, NICE; National Institute for Clinical Excellence, RTI; respiratory tract infection, SABA; short-acting beta-agonist, LABA; long-acting beta agonist, CDSS; clinical decision support-system.

Risk of bias in included studies

Overall nine of the 11 included papers had a low risk of bias,[18,19,22-28] Figure 2. See S5 Appendix for risk

of bias graphs summarising the risk for each EPOC criterion. One ITS had a moderate risk of bias,[20]

where there were significant losses to follow up amongst Canadian physicians that was inadequately

addressed, in addition the COVID-19 pandemic was likely to have influenced antibiotic prescribing

during the intervention period. There was also insufficient information on prevention of knowledge

of allocated interventions and crude post-intervention prescribing rates were not presented which

limited transparency.[20] The included controlled before and after study had a high risk of bias, by virtue

of its design.[21] In addition there was a significant improvement in inappropriate aspirin prescribing

prior to intervention implementation, this was clearly reported by the authors' but unexplained,[21]

given this finding the intervention effect was not considered significant for the purpose of this review.

Figure 2 Cochrane Effective Practice and Organisation of Care Risk of bias summary.
The two studies reported within the one paper were considered as one for the risk of bias assessment
as they had the exact same study processes.
279

 Effectiveness of interventions

Overall, six of the 12 included studies, two ITSs[18,19] and four RCTs[24,25,27,28] demonstrated a significant

effect on prescribing-related outcomes, Table 2. When exploring the intervention effect by outcome

measure, two of the six studies that targeted antibiotic prescribing had a significant effect.[18,24] One of

these had a true interactive component where prescribers had ongoing access to real-time data[18] and

both were multi-faceted interventions that included an educational component.[18,24] One was a

prospective ITS where practices after the pre-intervention and wash-out periods received access to a

web platform that provided educational material and interactive dashboards.[18] Data was updated on

a monthly basis and displayed as graphs illustrating monthly and yearly trends in the antibiotic

prescribing rate that could be explored by visit type, primary location and provider.[18] The effect of the

intervention was explored by provider type (paediatric, internal medicine, family physicians and

urgent care) with the family physician rate reported here, Table 2. The largest effect size was seen for

this group, although significant results were seen in all groups.[18] The other study that showed a

significant effect on antibiotic prescribing was an RCT that focused on inappropriate antibiotic

prescribing for respiratory tract infections,[24] with the outcome measured at the visit level (i.e. the

proportion of respiratory tract infection visits that resulted in the prescription of an antibiotic).

Participating practices received an educational package and monthly reports by email which displayed

the overall antibiotic prescribing rate and the rates of inappropriate antibiotic prescribing for defined

respiratory tract infections, both of which were compared to the average and best performing

practices.[24] The remaining four studies that targeted antibiotic prescribing failed to show an effect on

antibiotic prescribing rates[20,22,26] or broad-spectrum antibiotic prescribing.[23]

Six studies (reported in five papers) explored the effect on PIP for other drugs groups (see S6 Appendix

for a list of the indicators included in these studies) and four of these demonstrated a significant

effect.[19,25,27,28] Three of these four were part of multi-faceted interventions that included either a

clinical decision support or educational element,[19,25,28] and only one was a true interactive dashboard

where prescribers had ongoing access to real-time data.[19] The four studies that demonstrated a

significant effect on PIP included one ITS and three RCTs. The ITS explored the effect of the routine

roll-out of the SMASH intervention that provided feedback on the prevalence of each hazardous

prescribing and inadequate blood-test monitoring indicator with comparisons to the local area (clinical

commissioning group) average.[19] There was a significant effect on high-risk prescribing (ARR -0.96%,

95% CI -1.12% to -0.79%) but not on inadequate blood-test monitoring,[19] however there was a

significant effect seen on the latter outcome at 24 weeks follow-up. In addition the largest reductions

in high-risk prescribing were seen in practices with higher baseline rates and by 12 months follow-up

there was significantly reduced inter-practice variation in the rates of PIP and inadequate blood test

monitoring.[19] The remaining three studies demonstrating a significant effect on PIP were RCTs where

feedback with comparative rates of each of the included indicators were emailed to the practice every

quarter.[25,27,28]

Of the two studies that did not demonstrate an effect on PIP, one was a controlled before and after

study that had a high risk of bias.[21] Although the authors reported a significant effect on inappropriate

aspirin prescribing there was an unexplained significant improvement in this indicator during phase

one of the study prior to the implementation of the aspirin dashboard.[21] In addition no rates or

inferential statistics for the effect of the dashboard on inappropriate metformin prescribing were

reported as there were only 8 patients prescribed this medicine at follow up.[21] The other study that

did not demonstrate an effect on PIP was a cRCT that explored the effect on inappropriate

anticoagulant omissions for atrial fibrillation.[28]

With respect to the intervention components five of the six studies that had multi-faceted

interventions showed a significant effect,[18,19,24,25,28] compared to one[27] of the five studies that just had

the interactive dashboard component. Two cRCTs included clinical decision support elements where

individual patients were identified within the dashboard (hazardous prescribing/inadequate blood

test monitoring or inappropriate bronchodilator prescribing) and both had a significant effect.[27,28]

Table 2 Results of included studies

Lead author, year, country	Outcome description	Effect size
Randomised controlled trials		
Aghlmandi (2023, Switzerland)[22]	Abx prescribing rate per 100 consultations during the second year of the intervention	ARR −0.1% (95% CI, −1.2% to 51.0%)
Curtis (2021, UK)[23]	Percentage of abx that are broad spectrum	Coefficient −0.31%, (95% CI −0.7% to 0.1%) Coefficient 0.41%, (95% CI 0.007% to 0.800%) [¥]
Dutcher (2021, USA)[24]	Proportion of RTI visits with abx	OR 0.47 (95% CI 0.45 to 0.48)
Guthrie (2016, UK)[25]	Proportion of patients included in one or more of the 6 criteria who received a high-risk prescription	OR 0.88 (95% CI 0.80 to 0.96) OR 0.86 (95% CI 0.78 to 0.95)[Ᵽ]
Hemkins (2017, Switzerland)[26]	Antibiotic prescription rate measured as DDD per 100 consultations	ARR 0.81% (95% CI -2.56% to 4.30%)
MacBride-Stewart (2022, UK)[27]	Mean number of patients with an inappropriate SABA or LABA prescription	Mean difference -3.7 (95% CI -5.3 to -2.0)
Willis (2020, UK)[28]*	Proportion of patients with at least 1 high risk NSAID or anti-platelet indicator	OR 0.815 (97.5% CI 0.67 to 0.99)~
Willis (2020, UK)[28]*	Proportion of patients with AF prescribed appropriate anticoagulation therapy*	OR 0.902 (97.5% CI 0.75 to 1.09)
Controlled before and after study		
deLusigan (2021, UK)[21]	Proportion of patients incorrectly prescribed (a) metformin and (b) aspirin	(a) [§] (b) OR 0.44 (95% CI 0.27 to 0.72)[μ]
Interrupted time series		
Davidson (2023, USA)[18]	Percentage of total visits with abx prescription[¶]	Pre–post relative difference in rates -20.4 % Level change β Coefficient −7.95 (95% CI −11.05 to −4.85)
Peek (2020, UK)[19]	Prevalence of exposure to (a) any potentially hazardous prescribing (10 indicators) and (b) any inadequate blood-test monitoring (2 indicators) among patients with risk factors for such prescribing and monitoring 12 months after intervention start	(a) ARR -0.96% (95% CI -1.12% to -0.79%) (b) ARR −2.85% (95% CI −5.68% to 0.71%)
Soucy (2024, Israel/Canada)[20]	Proportion of total visits with abx prescription	OR 1.01; 95% CI 0.94 to 1.07

[¥] Arm 3 V arm 2 (arm 3 included behavioural change component, arm 2 was feedback alone)
[Ᵽ] Arm 3 V arm 1 (arm 3 included behavioural change component, arm 2 was feedback alone)
~ Results presented as 97.5% CI, converted to 95% for meta-analysis below.
* Odds ratio was inverted to for comparison to other PIP measures.
[§] No inferential statistics for the first outcome measure, proportion with inappropriate metformin prescriptions, as number
were very low (<10).
[μ] Unaccounted changes in the same direction of the intervention effect seen prior to implementation of the intervention.

 ¶Rates reported separately for family physicians, internal physicians and paediatricians. Effect for family physicians reported
339 here.
340 *Abbreviations: ARR; absolute risk reduction, OR; odds ratio, Abx; antibiotic, RTI; respiratory tract infection, DDD; defined daily*
341 *dosage, SABA; short-acting beta agonist inhaler, LABA; long-acting beta agonist inhaler, AF; atrial fibrillation, NSAID; non-*
342 *steroidal anti-inflammatory drug*
343

Four of the eight included RCTs measured the effect of the intervention on PIP and presented results

as proportions and odds ratios with 95% confidence intervals (two of these trials were reported within

the one paper).[24,25,28] However, one of these studies measured the proportion of inappropriate

prescriptions at the visit level,[24] the others were at the patient level.[25,28] Thus the three RCTs that

assessed the effect on appropriate prescribing at the patient level were included in the meta-analysis.

The overall effect size was OR 0.91 (95% CI 0.77 to 1.06), with significant heterogeneity (I^2 =71.8%,

p=0.03), see Figure 3. This heterogeneity may be explained by differences in outcome measures: the

trial on appropriate atrial fibrillation prescribing assessed improvement in prescribing, whereas the

other two studies measured the presence of at least one high-risk prescribing indicator.

Figure 3 Forest plot of randomised controlled trials exploring the intervention effect on patient level
prescribing appropriateness
Abbreviations: CI; confidence interval, RP; risky prescribing, AF; atrial fibrillation
Forest plot showing the effects of intervention on prescribing outcomes across included studies. For
the two Willis studies, the originally reported 97.5% confidence intervals (CIs) were converted to 95%
CIs for consistency. Additionally, for the atrial fibrillation study, the outcome measured was the

improvement in appropriate anticoagulant prescribing for atrial fibrillation; the odds ratio (OR) was
inverted to align with the direction of effect in the meta-analysis.

Discussion

Summary of results

This systematic review aimed to explore the characteristics of interactive dashboard interventions

designed to support safe prescribing and explore their effect on prescribing-related outcome

measures. Given the nature of the intervention, where data is often fed back on a widespread basis

and implemented as a policy, quasi-experimental designs, were included. Six of the 12 included studies

demonstrated a significant effect and all of these had an overall low risk of bias.[18,19,24,25,27,28] Notably,

only two of the six studies that explored the effect of these interventions' on antibiotic prescribing

showed a significant effect.[24] It may be that recent campaigns to improve antimicrobial stewardship

have already resulted in improvements, leaving less room for further advancements. Four of the five

studies looking at PIP showed a significant effect.[19,25,27,28] Potentially inappropriate or high-risk

prescribing is more common in complex patients with multimorbidity and polypharmacy[2] and lack of

prescriber awareness has been identified as a barrier to addressing this.[29] Thus, the difference in effect

seen by outcome measure may be because PIP is often related to clinician oversight, whereas

antibiotic prescribing reflects a more direct clinician decision and thus may be less amenable to

change. This hypothesis is supported by the fact that both interventions that alerted prescribers to

specific instances of PIP had a significant effect.[19,27] Similar to results presented in other systematic

reviews exploring the effectiveness of interventions in addressing inappropriate polypharmacy,[30]

multi-faceted interventions were more often effective with five of the six multi-faceted interventions

demonstrating a significant effect.[18,19,24,25,28] In summary, interventions targeting PIP, that included

multifaceted elements seemed to have a beneficial effect on outcomes.

Audit and feedback is known to lead to small improvements in professional behaviour, as evidenced

by a systematic review of 140 studies, including a meta-analysis of 108 comparisons from 70 studies,

which found a median absolute increase of 4.3% in healthcare professionals' compliance with desired

practices.[9] Increased frequency of feedback, coupled with explicit, measurable targets and specific

action plans, were associated with greater effectiveness.[9] The interventions included in this review all

included ongoing feedback of relatively contemporaneous data, with comparisons to specific set

targets or comparative benchmarking. There was significant heterogeneity among the results of the

three studies included in this meta-analysis. This was likely explained by the differing outcome

measure in the study assessing the effect on appropriate coagulation for atrial fibrillation, where the

outcome reflected inappropriate omission as opposed to an inappropriate prescription. Other

approaches such educational interventions and clinical decision support have also failed to improve

anticoagulation rates for patients with atrial fibrillation.[31] Collaborative, shared decision making

interventions may be needed to address this more complex prescribing decision around reducing the

future risk of an adverse event.[32] The two other studies included in the meta-analysis, both of which

demonstrated a significant effect, targeted PIP and included an educational component,[25,28] which

may have mediated some of the observed effect. The study by Willis et al, which showed a larger

treatment effect, also incorporated clinical decision support, which has been shown to have a modest

effect on prescribing behaviour.[33]

Strengths and limitations

This systematic review included a broad and detailed search strategy including citation chasing and

grey literature searches of clinical trial registries to reduce the risk of publication bias. Including quasi-

experimental designs meant we captured two large ITSs that explored the implementation of novel

interactive dashboards. Given the heterogeneous nature of the outcome measures included (different

prescribing criteria, measured at different levels (e.g. practice and visit level as well as patient level) it

was only possible to perform a meta-analysis for three studies and it was not possible to conduct a

funnel plot to formally assess publication bias. The scope of our review was shaped by focusing on

feedback mechanisms that align with the functionality of interactive dashboards. While this approach

excludes one-off feedback interventions, it allows for a more detailed exploration of tools designed

411 for repeated engagement with contemporaneous data, which are hypothesised to have distinct

412 advantages.[34] This focus also aligns with prior evidence suggesting that repeated feedback may be

413 more effective in driving behaviour change,[35] though we acknowledge that findings from recent

414 research indicate variability in this relationship.[36]

415 *Implications for research, policy and practice*

416 This review identified several gaps in the existing literature. Only 12 studies met the inclusion criteria,

417 with just four employing true interactive dashboards and six were multifaceted. The limited number

418 of studies suggests a need for further research exploring the effectiveness of interactive dashboards

419 designed to optimise prescribing. A key challenge in conducting the meta-analysis was the

420 heterogeneity of outcome measures. Identifying appropriate outcome measures is a challenge when

421 assessing the effectiveness of interventions such as interactive dashboards designed to improve

422 prescribing quality in primary care settings. Important clinical endpoints such as unplanned hospital

423 admissions or mortality require a sufficient sample size and an adequate follow-up period to identify

424 any potential effect mediated by higher quality prescribing, which may not be feasible. Thus,

425 composite measures of explicit prescribing criteria are often used as primary endpoints for these

426 studies.[37] There is strong observational evidence that such prescribing is associated with adverse

427 outcomes for patients such as increased mortality, falls and unplanned hospital admissions.[38] More

428 general prescribing measures include rates of utilisation and these serve as a valuable outcome for

429 evaluating the impact of health policy implementation programmes aimed at modifying prescribing

430 behaviours, such as reducing high opioid prescription levels[39] or imposing restrictions on drugs with

431 unfavourable cost-effectiveness profiles.[40] However, the outcomes identified for this review were

432 reported at various levels, including the prescription, patient, prescriber, and practice levels. The

433 development of a core outcome set for prescribing-related measures that can be consistently applied

434 across studies utilising routine prescribing or dispensing datasets may be one way of addressing this

435 and would facilitate more meaningful comparisons and benefit future meta-analyses. Future research

should also investigate how different feedback features such as frequency, content, and format

influence both effectiveness and engagement, and whether there is an optimal level of engagement

required for behaviour change. This will necessitate systems capable of providing both ongoing

feedback and measuring user engagement through detailed use analytics, the latter of which was

notably absent in most studies included in this systematic review. Finally, routine evaluations of

policies that utilise this data to optimise prescribing are essential. Systematic and standardised

evaluations would provide valuable insights into the effectiveness of policy interventions aimed at

optimising prescribing, thereby enhancing clinical outcomes and health system efficiency.

Conclusion

Interactive dashboards have the potential to support safe and effective prescribing in primary care.

Multi-faceted interventions that target high-risk prescribing are more likely to be effective. Future

research should focus on developing core outcome sets to facilitate future meta-analyses of

effectiveness as well as optimising their implementation and understanding how to sustain user

engagement. To support their implementation, it is essential to establish the necessary data

infrastructure within primary care systems. With advancements in data infrastructure and analysis,

these interventions could have a significant impact if implemented at scale.

Supporting Information

S1 Appendix: PRISMA Checklist

S2 Appendix: Electronic search reports

S3 Appendix: List of all data points extracted from included studies

S4 Appendix: List of all studies with reasons for exclusion from full text review

S5 Appendix: Risk of bias graphs

S6 Appendix: List of all endpoints for included studies

Acknowledgments:

Killian Walsh; Information Specialist, RCSI library assisted with search strategy. Mobeena Naz; Medical

Student, RCSI assisted with title and abstract screening.

References

1. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. *Health and Quality of Life Outcomes.* 2004;2:51.

2. Pérez T, Moriarty F, Wallace E, McDowell R, Redmond P, Fahey T. Prevalence of potentially inappropriate prescribing in older people in primary care and its association with hospital admission: longitudinal study. *BMJ.* 2018;363:k4524.

3. Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with multimorbidity in primary care. *BMJ.* 2015;350:h176.

4. Jung Yin Tsang MS, Thomas Blakeman, Rupert Payne, Darren M Aschcroft. Protocol for the development and validation of a Polypharmacy Assessment Score for potentially problematic polypharmacy PREPRINT (Version 1) available at Research Square 2023.

5. Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. *Drugs Aging.* 2010;27(12):947-957.

6. Radomski TR, Decker A, Khodyakov D, et al. Development of a Metric to Detect and Decrease Low-Value Prescribing in Older Adults. *JAMA network open.* 2022;5(2):e2148599-e2148599.

7. Dimitrow MS, Airaksinen MS, Kivela SL, Lyles A, Leikola SN. Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review. *J Am Geriatr Soc.* 2011;59(8):1521-1530.

8. Curtis HJ, Goldacre B. OpenPrescribing: normalised data and software tool to research trends in English NHS primary care prescribing 1998–2016. 2018;8(2):e019921.

9. Ivers N, Jamtvedt G, Flottorp S, et al. Audit and feedback: effects on professional practice and healthcare outcomes. *Cochrane Database Syst Rev.* 2012(6):Cd000259.

10. Kwan JL, Lo L, Ferguson J, et al. Computerised clinical decision support systems and absolute improvements in care: meta-analysis of controlled clinical trials. 2020;370:m3216.

11. Williams R, Keers R, Gude WT, et al. SMASH! The Salford medication safety dashboard. 2018;25(3):183-193.

12. Moynagh P, Mannion, Á, Wei, A, Clyne, B, Moriarty, F, McCarthy, C. Effectiveness of interactive dashboards to optimise prescribing in primary care: a protocol for a systematic review [version 1; peer review: awaiting peer review]. *HRB open research.* 2024;7(44).

13. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). In: Cochrane; 2023: www.training.cochrane.org/handbook.

14. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021:n71.

15. Haddaway NR, Grainger MJ, Gray CT. Citationchaser: A tool for transparent and efficient forward and backward citation chasing in systematic searching. *Research synthesis methods.* 2022;13(4):533-545.

16. Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? . 2017. https://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/EPOC%20Study%20Designs%20About.pdf. Accessed 13/03/2024.

17. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. 2014;348:g1687.

18. Davidson LE, Gentry EM, Priem JS, Kowalkowski M, Spencer MD. A multimodal intervention to decrease inappropriate outpatient antibiotic prescribing for upper respiratory tract infections in a large integrated healthcare system. *Infect Control Hosp Epidemiol.* 2023;44(3):392-399.

19. Peek N, Gude WT, Keers RN, et al. Evaluation of a pharmacist-led actionable audit and
feedback intervention for improving medication safety in UK primary care: An interrupted
time series analysis. *PLoS Med.* 2020;17(10):1-17.
20. Soucy Jean-Paul R, Low M, Acharya Kamal R, et al. Evaluation of an automated feedback
intervention to improve antibiotic prescribing among primary care physicians (OPEN
Stewardship): a multinational controlled interrupted time-series study. *Microbiology*
spectrum. 2024;12(4):e00017-00024.
21. de Lusignan S, Hinton W, Seidu S, et al. Dashboards to reduce inappropriate prescribing of
metformin and aspirin: A quality assurance programme in a primary care sentinel network.
Prim Care Diabetes. 2021;15(6):1075-1079.
22. Aghlmandi S, Halbeisen FS, Saccilotto R, et al. Effect of Antibiotic Prescription Audit and
Feedback on Antibiotic Prescribing in Primary Care: A Randomized Clinical Trial. *JAMA internal*
medicine. 2023;183(3):213-220.
23. Curtis HJ, Bacon S, Croker R, et al. Evaluating the impact of a very low-cost intervention to
increase practices' engagement with data and change prescribing behaviour: a randomized
trial in English primary care. *Fam Pract.* 2021;38(4):373-380.
24. Dutcher L, Degnan KO, Adu-Gyamfi AB, et al. Improving Outpatient Antibiotic Prescribing for
Respiratory Tract Infections in Primary Care; a Stepped-Wedge Cluster Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of
America. 2021;74(6):947-956.
25. Guthrie B, Kavanagh K, Robertson C, et al. Data feedback and behavioural change intervention
to improve primary care prescribing safety (EFIPPS): multicentre, three arm, cluster
randomised controlled trial. *BMJ (Clinical research ed).* 2016;354:i4079.
26. Hemkens LG, Saccilotto R, Leon Reyes S, et al. Personalized Prescription Feedback Using
Routinely Collected Data to Reduce Antibiotic Use in Primary Care: A Randomized Clinical Trial.
JAMA internal medicine. 2017;177(2):176-183.
27. MacBride-Stewart S, Marwick C, Ryan M, Guthrie B. Feedback of actionable individual patient
prescription data to improve asthma prescribing: pragmatic cluster randomised trial in 233 UK
general practices. *Br J Gen Pract.* 2022;72(722):e627-633.
28. Willis TA, Collinson M, Glidewell L, et al. An adaptable implementation package targeting
evidence-based indicators in primary care: A pragmatic cluster-randomised evaluation. *PLoS*
Med. 2020;17(2):1-20.
29. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising
potentially inappropriate medications in adults: a systematic review and thematic synthesis.
BMJ open. 2014;4(12).
30. Clyne B, Fitzgerald C, Quinlan A, et al. Interventions to Address Potentially Inappropriate
Prescribing in Community-Dwelling Older Adults: A Systematic Review of Randomized
Controlled Trials. *J Am Geriatr Soc.* 2016;64(6):1210-1222.
31. Kapoor A, Amroze A, Vakil F, et al. SUPPORT-AF II: Supporting Use of Anticoagulants Through
Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation: A Cluster-Randomized
Study of Electronic Profiling and Messaging Combined With Academic Detailing for Providers
Making Decisions About Anticoagulation in Patients With Atrial Fibrillation. *Circ Cardiovasc*
Qual Outcomes. 2020;13(2):e005871.
32. Siontis KC, Montori VM, Noseworthy PA. Multimodal Interventions to Increase Anticoagulant
Utilization in Atrial Fibrillation: Futile Without Patient Engagement? *Circ Cardiovasc Qual*
Outcomes. 2020;13(2):e006418.
33. Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-
screen, point of care computer reminders on processes and outcomes of care. *Cochrane*
Database Syst Rev. 2009;2009(3):Cd001096.

34. Colquhoun HL, Carroll K, Eva KW, et al. Advancing the literature on designing audit and
feedback interventions: identifying theory-informed hypotheses. *Implementation Science.*
2017;12(1):117.
35. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing literature, stagnant science? Systematic
review, meta-regression and cumulative analysis of audit and feedback interventions in health
care. *J Gen Intern Med.* 2014;29(11):1534-1541.
36. Schwartz KL, Shuldiner J, Langford BJ, et al. Mailed feedback to primary care physicians on
antibiotic prescribing for patients aged 65 years and older: pragmatic, factorial randomised
controlled trial. *BMJ.* 2024;385:e079329.
37. Cole JA, Gonçalves-Bradley DC, Alqahtani M, et al. Interventions to improve the appropriate
use of polypharmacy for older people. *Cochrane Database Syst Rev.* 2023(10).
38. Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its
associations with health-related and system-related outcomes in hospitalised older adults: A
systematic review and meta-analysis. *Br J Clin Pharmacol.* 2021;87(11):4150-4172.
39. Daoust R, Paquet J, Marquis M, et al. Evaluation of Interventions to Reduce Opioid Prescribing
for Patients Discharged From the Emergency Department: A Systematic Review and Meta-
analysis. *JAMA network open.* 2022;5(1):e2143425-e2143425.
40. Mattsson M, Boland F, Kirke C, et al. The impact of lidocaine plaster prescribing reduction
strategies: A comparison of two national health services in Europe. *Br J Clin Pharmacol.*
2023;89(8):2349-2358.
580

Supplemental material

S1 Appendix: PRISMA Checklist

S2 Appendix: Electronic search reports

S3 Appendix Study Inclusion Criteria

S4 Appendix: List of all data points extracted from included studies

S6 Appendix Characteristics of Included Studies

S7 Appendix: Risk of bias graphs

S8 Appendix: List of all endpoints for included studies